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Abstract
Background: Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg
(RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of
venous thromboembolism (VTE) after elective total hip arthroplasty.
Methods: This prespecified pooled analysis compared the outcomes for the dabigatran 220 mg dose with enoxaparin,
which included 4,374 patients. Total VTE (venographic and symptomatic) plus all-cause mortality (primary efficacy),
major VTE (proximal deep vein thrombosis [DVT] or non-fatal pulmonary embolism) plus VTE-related death, and
bleeding events were evaluated. Efficacy analysis was based on the modified intention-to-treat (ITT) population
and safety analysis was based on all treated patients. The common risk difference (RD) for dabigatran versus
enoxaparin was estimated using a fixed effects model.
Results: Total VTE and all-cause mortality occurred in 6.8 % (114/1,672) and 7.7 % (129/1,682) (RD:–0.8 %, 95 %
confidence interval [CI] –2.6 to 0.9) for dabigatran and enoxaparin, respectively. Major VTE plus VTE-related mortality
occurred in 2.7 % (46/1,714) and 4.0 % (69/1,711) (RD: –1.4 %, 95 % CI –2.6 to –0.2) of patients receiving dabigatran
220 mg and enoxaparin, respectively. Major bleeding occurred in 1.7 % (37/2,156) and 1.3 % (27/2,157) (RD: 0.5 %,
95 % CI –0.2 to 1.2), for dabigatran and enoxaparin respectively.
Conclusions: Extended prophylaxis with oral dabigatran 220 mg once daily was as effective as enoxaparin 40 mg once
daily in reducing the risk of total VTE and all-cause mortality after total hip arthroplasty, with a similar bleeding profile.
The clinically relevant outcome of major VTE and VTE-related death was significantly reduced with dabigatran versus
enoxaparin.
Trial registration: NCT00657150 and NCT00168818
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Background
Dabigatran etexilate (hereafter referred to as dabigatran)
is an orally administered direct, reversible thrombin
inhibitor for the prevention and treatment of various
thromboembolic disorders. Two previously reported
phase 3 trials (RE-NOVATE and RE-NOVATE II) [1, 2]
compared the efficacy and safety of dabigatran (220 mg
or 150 mg once daily, started 1–4 h after surgery) with
enoxaparin (40 mg once daily, started at least 12 h
before surgery) for the prevention of venous thrombo-
embolism (VTE) and all-cause mortality after elective
total hip arthroplasty. In both of these studies, the non-
inferiority of dabigatran 220 mg over enoxaparin 40 mg
for the primary efficacy endpoint, total VTE (the com-
posite of symptomatic and asymptomatic venographic
deep vein thrombosis [DVT], non-fatal pulmonary em-
bolism [PE]) plus all-cause mortality, was demonstrated.
Bleeding and adverse event (AE) rates with dabigatran
were low and similar to those reported for enoxaparin.
Dabigatran 220 mg once daily (starting with a half dose
1–4 h after the end of surgery) is now approved in more
than 100 countries for thromboprophylaxis in patients
undergoing total hip arthroplasty.
The prespecified pooled analysis of these two studies
was planned to compare the effect of dabigatran 220 mg
and enoxaparin 40 mg once daily on the primary efficacy
endpoint of total VTE and all-cause mortality in patients
undergoing total hip arthroplasty.
Methods
Study design and setting
RE-NOVATE and RE-NOVATE II were prospective,
double-blind, double-dummy, randomized, multicentre,
non-inferiority studies.
Participants were adults aged at least 18 years who
were scheduled for primary elective total hip arthro-
plasty. The two trials had identical study eligibility cri-
teria and were designed to be as similar as possible.
Briefly, patients were randomized to treatment with oral
dabigatran 220 mg or 150 mg once daily (the latter dose
was not used in RE-NOVATE II), or subcutaneous enox-
aparin 40 mg once daily started the evening before sur-
gery; in some countries enoxaparin treatment was
started postoperatively in accordance with local practice.
The first dose of dabigatran was halved and given 1–4 h
after wound closure, provided clinical assessment of peri-
operative and postoperative bleeding and drainage indi-
cated adequate hemostasis. If administration was delayed
until the day after surgery, a full dose was given, followed
by a second dose at least 12 h later. Treatment was con-
tinued until mandatory bilateral venography at 28–35
days. In both trials, the treatment period was defined as
the time from first dose to 3 days after the last dose. Con-
tinued VTE prophylaxis was at the discretion of the
treating physician. Patients attended a clinical follow-up
visit 3 months after surgery. Concomitant administration of
low dose aspirin (<160 mg) and selective cycloxygenase-2
inhibitors was allowed during treatment. Elastic compres-
sion stockings were permitted, but intermittent pneumatic
compression devices were prohibited.
Both studies were approved by National Independent
Ethics Committees and conducted according to the
Declaration of Helsinki (October 1996 version). All
patients gave signed informed consent prior to entry.
Outcome measures
The prespecified primary efficacy endpoint of this
pooled analysis was identical with that of the individual
trials, i.e., the composite of total VTE and all-cause
mortality. The endpoint was analyzed in the modified
intention-to-treat (mITT) population, comprising all
randomized and treated patients who underwent elect-
ive total hip arthroplasty and had evaluable adjudicated
data on VTE (venographic confirmation in both legs or
symptomatic event) or died during the treatment
period. The main secondary efficacy outcome was the
composite of major VTE (venographic or symptomatic
proximal DVT and/or PE) and VTE-related mortality
during treatment. Additional predefined secondary effi-
cacy outcomes during the treatment period included
total DVT (venographic or symptomatic), proximal
DVT (venographic or symptomatic), and symptomatic
DVT and/or PE.
All efficacy endpoints were based on assessments made
by the same blinded Independent Venous Thrombo-
embolic Event Adjudication Committee. Mandatory bilat-
eral venography was performed within 24 h of the last oral
dose, as described previously [3]. Suspected symptomatic
DVT during treatment or follow-up was confirmed by
ultrasound or venography. Symptoms suggestive of PE
mandated confirmation by ventilation-perfusion scintig-
raphy, pulmonary angiography or spiral chest computer
tomography, depending on local center preference. Deaths
were considered related to VTE if they were categorized
as “VTE related” or “unexplained" by the Independent
Adjudication Committee.
All randomized patients who received at least one dose
of study treatment were evaluable for safety. The main
safety endpoint was the frequency of major bleeding
events (which, different to previously performed studies,
also included bleeding from the surgery wound site)
occurring between intake of the first dose of study medi-
cation and 3 days after the last dose. Secondary safety
outcomes included the composite of major and clinic-
ally relevant non-major bleeding events, any bleeding
events during treatment, liver enzyme elevations (≥3 x
the upper limit of the normal reference range (ULN)
for serum alanine aminotransferase [ALT]) and acute
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coronary events (defined as confirmed unstable angina,
myocardial infarction [MI], and cardiac death). This is
in line with a number of pooled analyses from total
knee and hip replacement trials with dabigatran, which
included more than 8,000 patients [4, 5]. Major, clinic-
ally relevant, non-major and minor bleeding events
were defined according to accepted guidelines [6], as
reported previously [3]. In particular, the definition of
major bleeding includes wound site bleeding events, in
accordance with recommended guidelines [6]. ALT ele-
vations ≥3 x ULN and any suspected acute coronary
syndrome events were reviewed by an Independent
Committee who were blinded to treatment allocation.
An assessment of causality was provided for each of the
reviewed patient cases.
Statistical analysis
The statistical analysis plan described here was planned
before commencement of the RE-NOVATE II trial in ac-
cordance with regulatory recommendations [7].
For each trial, the difference in the proportion of
patients with an event (efficacy or safety) was compared
between dabigatran 220 mg and enoxaparin 40 mg as a
risk difference (RD) as this was considered the most
clinically meaningful measure. A common RD estimate
across the two trials was calculated using a fixed-effects
model (maximum likelihood estimation) [8], based on
inverse variance weights for combined results from the
individual trials, and compared with results obtained
with a random effects model (DerSimonian and Laird
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the studies. Heterogeneity of the common RD between
the studies was assessed using Cochran’s χ2 and the I2
statistic; p <0.10 was considered to denote statistically
significant heterogeneity and where I2 was greater than
50 %, heterogeneity was considered substantial [9].
Pooled event rate data for each treatment group are pre-
sented alongside the common RD results obtained from
the pooled analysis.
Subgroup analyses were planned to investigate the
influence of age, body weight, gender, and renal function
(determined from calculated baseline creatinine clearance)
on the incidence of the primary efficacy outcome, as well
as bleeding events. For these comparisons the odds ratio
and 95 % confidence intervals (CIs) for the analyzed sub-
groups were calculated using a fixed-effects model for the
efficacy and safety endpoints.
Sensitivity analyses were conducted to explore the ro-
bustness of the results. The impact of missing or non-
evaluable venography data, based on imputation of
missing values using best and worst case scenarios (all
treatment success or all treatment failure), was investi-
gated to ensure that missing data did not affect the
Table 1 Demographic and baseline characteristics
Dabigatran 220 mg Enoxaparin 40 mg
(n = 2,156) (n = 2,157)
Number of treated patients 2,156 2,157
Age, yr 63 ± 11 63 ± 11
Females, n (%) 1177 (54.6) 1152 (53.4)
Weight, kg 79 ± 16 79 ± 16
Body mass indexa 27.8 ± 4.7 27.6 ± 4.6
Previous VTE, n (%) 65 (3.0) 54 (2.5)
Creatinine clearanceb, mL/min 92 ± 31 93 ± 31
Racec, n (%)
White 2,051 (95.1) 2,052 (95.1)
Asian 96 (4.4) 88 (4.1)
Black 5 (0.2) 12 (0.6)
Other 4 (0.2) 5 (0.2)
Geographical region, n (%)
Western Europe 1,282 (59.5) 1,291 (59.9)
Central Europe 474 (22.0) 470 (21.8)
North America 170 (7.9) 168 (7.8)
India 91 (9.0) 88 (4.1)
Australia/New Zealand/South Africa 139 (6.4) 140 (6.5)
Patients treated and operated, n (%) 2,138 (99.2) 2,134 (98.9)
Anesthesiad, n (%)
General alone 525 (24.4) 503 (22.3)
Neuraxial alonee 1,461 (67.8) 1,486 (65.8)
Combinationf 149 (6.9) 144 (6.4)
Mean duration of surgery ± SD, min 85.4 ± 30.2 85. ±30.4
Study treatment
Mean time to first subcutaneous injectiong,h in relation to surgery, hr –15.6 ± 20.7 –15.2 ± 13.5
Mean time to first oral dose postsurgeryh, hr 3.1 ± 2.6 3.2 ± 2.7g
Median (range) duration of hospital stayi, d 8.5 (3–51) 8.5 (3–26)
Median (range) treatment duration, d 31.6 (1–89) 31.7 (1–49)
Data are given as mean ± SD except where indicated
SD standard deviation, VTE Venous thromboembolism
aBody mass index was defined as weight in kilograms divided by square of height in meters; bCreatinine clearance rates were calculated using the
Cockcroft–Gault formula; cAs reported by the investigator; dPatients may have had more than one type of anesthetic; eIncludes spinal and epidural anesthesia;
fPeripheral nerve block plus general or neuraxial anesthesia; g26 patients in RE-NOVATE II group received their first dose postsurgery; hIncludes both active
treatment and placebo; iTime from surgery until day of discharge, data available in RE-NOVATE for 1,136 and 1,140 patients, respectively
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A total of 4,374 patients were randomized across 20
countries between December 2004 and May 2009, of
whom 4,313 were treated and therefore evaluable for
safety. 4,272 patients were operated upon and treated
with oral dabigatran 220 mg (n = 2,138) or subcutaneous
enoxaparin 40 mg (n = 2,134) (Fig. 1). A further 918
(21.5 %) patients were excluded from the mITT popula-
tion, as usual in all studies with venography, mainly
because bilateral venography was not performed (usually
declined by the patient) or the venograms were consid-
ered indeterminate by the venography adjudication com-
mittee. This percentage is consistent with that reported
in contemporary studies using venography as an end-
point [3, 10, 11]. In total, 240 (11.2 %) patients allocated
dabigatran and 230 (10.7 %) allocated enoxaparin dis-
continued treatment. The primary reasons for discon-
tinuation were similar between groups. The two groups
were well balanced in terms of demographic and surgical
characteristics (Table 1).
Efficacy outcomes
Efficacy outcomes are summarized in Table 2. The pri-
mary outcome (the composite of total VTE and all-cause
mortality) occurred in 114 (6.8 %) patients treated with
dabigatran 220 mg and 129 (7.7 %) treated with enoxa-
parin 40 mg (RD: –0.8 %, 95 % CI –2.6 to 0.9; p = 0.35).
Distal (below knee) DVT detected by venography was the
most frequent component of the primary endpoint. There
were four deaths during treatment; three in the dabigatran
group (one related to VTE), and one in the enoxaparin
group not related to VTE.
The main secondary outcome (composite of major
VTE and VTE-related mortality) occurred in 2.7 % with
dabigatran versus 4.0 % with enoxaparin (RD: –1.4 %,
95 % CI –2.6 to –0.2; p = 0.03). Symptomatic DVT oc-
curred in 0.3 % versus 0.2 % (p = 1.00), respectively. Over
the whole 3-month (treatment plus follow-up) study
period the rate of symptomatic VTE plus all-cause mor-
tality was 0.9 % in each treatment group.
There was a significant difference in the risk for
proximal DVT (venographic or symptomatic) for dabiga-
tran versus enoxaparin (RD: –1.4 %, 95 % CI –2.6 to –0.3;
p = 0.02). No difference in total DVT (venographic or
symptomatic) (RD: –1.1 %, 95 % CI –2.7 to 0.6; p = 0.22)
was observed. The incidence of symptomatic DVT and
Table 2 Efficacy outcomes, modified ITT population. Data are given as n/N (%)
Outcome Dabigatran 220 mg Enoxaparin 40 mg Risk difference vs. enoxaparin, % (95 % CI)a p value
Total VTE and all-cause mortality
Pooled data 114/1,672 (6.8) 129/1,683 (7.7) –0.8 (–2.6, 0.9) 0.35
RE-NOVATE 53/880 (6.0) 60/897 (6.7) –0.7 (–2.9, 1.6)
RE-NOVATE II 61/792 (7.7) 69/786 (8.8) –1.1 (–3.8, 1.6)
Major VTEb and VTE-related mortalityc
Pooled data 46/1,714 (2.7) 69/1,712 (4.0) –1.4 (–2.6, –0.2) 0.03
RE-NOVATE 28/909 (3.1) 36/917 (3.9) –0.8 (–2.5, 0.8)
RE-NOVATE II 18/805 (2.2) 33/795 (4.2) –1.9 (–3.6, –0.2)
Symptomatic events
Symptomatic VTEd 17/2,138 (0.8) 16/2,134 (0.7)
Symptomatic DVT 6/2,138 (0.3) 5/2,134 (0.2) 1.00
Symptomatic PE 6/2,138 (0.3) 5/2,134 (0.2) 1.00
Death 3/2,138 (0.1) 1/2,134 (0.0) 0.62
Total asymptomatic DVT 100/1,665 (6.0) 122/1,677 (7.3)
Proximal 35/1,709 (2.0) 63/1,706 (3.7)
Distal only 65/1,666 (3.9) 59/1,679 (3.5)
Total study period (treatment + follow-up)
Symptomatic VTE + all-cause mortality 18/2,048 (0.9) 19/2,059 (0.9) 0.09
N = number of patients included within each population with percentage in parentheses
CI confidence interval, DVT deep vein thrombosis, ITT intention-to-treat, PE pulmonary embolism, VTE venous thromboembolism
aBased on normal approximation of binomial distribution for single trial and the fixed effects approach using a weighted average (inverse variance) for pooled
analyses; bMajor VTE was defined as venographic and symptomatic proximal DVT and/or non-fatal PE; cVTE-related mortality included fatal PE and deaths where
VTE cannot be excluded; dIncludes any symptomatic DVT (proximal or distal) and non-fatal or fatal symptomatic PE in patients in the safety population who had
undergone surgery
Eriksson et al. Thrombosis Journal  (2015) 13:36 Page 5 of 9
PE during treatment was comparable across treatments
(p = 1.0) (Table 2). Similar results were reported for the
main secondary outcome.
Bleeding-related outcomes are summarized in Table 3.
There was no difference in major bleeding rates between
the two groups; 37 (1.7 %) with dabigatran versus 27
(1.3 %) with enoxaparin (RD: 0.5 %, 95 % CI –0.2 to 1.2;
p = 0.19). Only one fatal bleeding event in the dabigatran
group was reported. Of the 37 major bleeding events
with dabigatran, 19 (51.4 %) occurred before any active
study drug had been administered. In contrast, all bleed-
ing events in the enoxaparin group occurred after the
first dose, which was given preoperatively in 94 % of pa-
tients. Similarly, there was no difference between the
groups in the rate of major or non-major clinically rele-
vant bleeding events (5.0 % versus 4.0 % dabigatran and
enoxaparin, respectively, p = 0.13), overall bleeding rates
or the requirement for blood transfusion.
Subgroup analyses
Treatment with dabigatran resulted in consistent reduc-
tions in the primary outcome irrespective of age (<65,
65–75, >75 years, p = 0.05), weight (≤70, >70–90, >90 kg)
(p = 0.50), gender (p = 0.54) or renal function (calculated
creatinine clearance >80, 50–80, <50 mL/min at baseline,
p = 0.32). There were no differences in the primary
outcome across additional subgroups according to treat-
ment (Fig. 2).
The results remained robust in sensitivity analyses
(data not shown), indicating that missing venography
data did not bias any estimation of the treatment effect.
There were no differences between results obtained
using the fixed versus random effects model.
Adverse events
The AE profile of each treatment was similar (Table 4).
Postoperative wound infection was reported as an AE in
37 patients, 16 (0.7 %) in the dabigatran group and 21
(1.0 %) in the enoxaparin group. AEs leading to treat-
ment discontinuation occurred in 6.2 % and 5.5 % of the
dabigatran and enoxaparin groups, respectively (Table 4).
Less than 1 % of patients in either group had an adjudi-
cated MI or ischemic stroke during or after treatment.
Fifteen patients (8 [0.4 %] in the dabigatran group and 7
[0.3 %] in the enoxaparin group) had cardiovascular
events (defined as ischemic stroke or MI) after >3 days
off study drug.
Moderate liver enzyme elevation (ALT levels >3 x
ULN) at any time after baseline occurred in 3.4 % of the
dabigatran group and 5.5 % of the enoxaparin group
(Table 4). In three patients in the dabigatran group,
there was an associated two-fold increase in bilirubin
Table 3 Bleeding-related outcomes, safety population
Outcome Dabigatran 220 mg Enoxaparin Risk difference vs. enoxaparin, % p value
(n = 2,156) (n = 2,157) (95 % CI)
Bleeding Events
Major, Total no. patients, % (95 % CI)a 37 (1.7, 1.2-2.4 %) 27 (1.3, 0.8-1.8 %) 0.5 % (–0.2, 1.2) 0.20
Fatal 1 (0.05) 0 (0)
In a critical organ 2 (0.1) 0 (0)
Clinically overt associated with 20 g/L or more fall in
hemoglobin
31 (1.4) 19 (0.9)
Clinically overt leading to transfusion of two or more
units of packed cells or whole blood
33 (1.5) 22 (1.0)
Warranting treatment cessation 1 (0.05) 1 (0.05)
Leading to re-operation 2 (0.1) 3 (0.1)
Onset of events – No. events/total no. patients (%)
-Before the first oral dose 19/37 (51.4) 10/28 (35.7)
-After the first oral dose 18/37 (48.6) 18/28 (64.3)
Clinically relevant non-major bleeding 71 (3.3) 60 (2.8)
Major or clinically relevant non-major bleeding 108 (5.0) 87 (4.0) 1.0 % (–0.3, 2.2) 0.13
Minor bleeding 131 (6.1) 128 (5.9)
Any bleeding events 239 (11.1) 215 (10.0)
Patients receiving blood transfusions - n/N (%) 858/2,138 (40.1) 880/2,134 (41.2)
Data are given as number (%) of patients except where indicated
CI confidence interval
aPatients may have been included in more than one category
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elevation. None of these cases met the criteria (Hy’s law)
for severe drug-induced hepatotoxicity [12].
Discussion
The prespecified pooled analysis of these two studies
was planned to compare the effect of dabigatran 220 mg
and enoxaparin 40 mg once daily on the primary efficacy
endpoint of total VTE and all-cause mortality in patients
undergoing total hip arthroplasty. This pooled analysis
of data from ~4,300 patients undergoing elective total
hip arthroplasty in the two RE-NOVATE studies adds to
the evidence base for dabigatran for prevention of
thromboembolic complications.
Dabigatran 220 mg was as effective as enoxaparin
40 mg in decreasing the risk of VTE and all-cause mor-
tality at 5 weeks. These results were consistent across
age, weight, gender, or creatinine clearance subgroups. It
is notable that the rate of major VTE and VTE-related
death was significantly lower with dabigatran (p = 0.03),
with a 1.4 % absolute reduction in risk versus enoxaparin.
This rate compares with the absolute reduction (0.7 to
1.7 %) observed in studies with the oral FXa inhibitors
(apixaban and rivaroxaban) versus enoxaparin in patients
undergoing hip arthroplasty and receiving prophylaxis for
an equivalent extended duration [10, 11]. Thus, dabigatran
may have similar benefits in reducing more clinically rele-
vant, proximally located lower limb thrombi as other
available oral anticoagulants.
The risk of bleeding was similar to that for enoxaparin.
Bleeding rates (major, clinically relevant non-major, and
minor bleeding) did not differ statistically between dabi-
gatran and enoxaparin across the two studies. All but
33 % of the major bleeding events were reported to have
occurred after day 3, although the onset of bleeding
could have started earlier.
Taken together, these results indicate that dabigatran
is a useful prophylactic therapy in this clinical setting. By
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power and prediction was achieved and allowed for an
improved understanding. Specifically, the rarer, but
clinically more relevant outcomes (major VTE and
VTE-related mortality, or proximal VTE) regarding the
performance of the oral anticoagulant dabigatran in
comparison to subcutaneous enoxaparin could be in-
vestigated. Sensitivity analysis also demonstrated that
missing data did not affect the power of the trial or bias
any estimation of the treatment effect.
Other important outcomes included treatment-related
wound complications and postoperative wound infec-
tions, all of which occurred with a similar frequency in
each group. Such complications are clinically relevant,
since bleeding assessment and wound-related AEs can
affect surgical outcome and influence decisions regard-
ing the provision of extended out-of-hospital prophy-
laxis. The AE profile, including liver enzyme elevations
and cardiovascular events, was similar between dabiga-
tran and enoxaparin.
Dabigatran is administered orally and is therefore
more convenient than parenterally administered antico-
agulants such as enoxaparin, particularly for out-of hos-
pital prophylaxis. This is of relevance when considering
current practice in the use of VTE prophylaxis. Despite
guidelines recommending use of prophylaxis for up to
35 days after hip arthroplasty [13], compliance may be
less than ideal. In one report, only ~75 % of patients
treated with parenteral low-molecular weight heparin
(e.g., enoxaparin) in hospital continued to receive it after
discharge [14]. It is anticipated that these practical ad-
vantages are likely to confer cost advantages, supported
by recent analysis. Indeed, economic evaluation, from
the perspective of the UK National Health System,
showed that extended prophylaxis with dabigatran was
cost-effective compared with enoxaparin, given the sub-
stantial reduction in costs due to oral administration
(pre- and postdischarge from hospital) [15]. Similar
savings have been reported in other country-specific
analyses from the healthcare system perspective [16, 17].
Conclusions
In conclusion, this pooled analysis of two trials compar-
ing dabigatran with enoxaparin demonstrated that dabi-
gatran was comparable to enoxaparin in preventing total
VTE and all-cause mortality when used for the same
duration, with a similar risk of bleeding and AEs. In clin-
ical practice, dabigatran can be considered an attractive
thromboprophylaxis in patients undergoing elective hip
arthroplasty, with potential economic advantages.
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Total with AEs 1,563 (72.5) 1,588 (73.6)
Serious AEs 146 (6.8) 141 (6.5)
AEs leading to treatment
discontinuation
134 (6.2) 118 (5.5)
Drug-related AEs (investigator
evaluation)
191 (8.9) 199 (9.2)
Wound infectionsa 16 (0.7) 21 (1.0)
Cardiovascular events
Myocardial infarction 2 (<0.1)b 6 (0.3)
Ischemic stroke 0 1 (0.1)
ALT elevation; no. (%) patients
>3 x ULN anytime post baseline 71/2,101 (3.4)c 115/2,097 (5.5)c
>3 x ULN plus bilirubin >2 x ULN
during treatment period
3/2,092 (0.1)d 0/2,096
Data are given as number (%) of patients except where indicated
AE adverse event, ALT alanine aminotransferase, ULN upper limit of normal
aIncludes wound hematomas, wound secretions, wound drainage and wound
hemorrhage; bA further event in RE-NOVATE II occurred in the follow-up
period; cNumber of patients with abnormality/total number of patients having
tests; dA further patient in RE-NOVATE II had an elevation 3 months postsurgery
while still in the follow-up period. None of the patients met the criteria for severe
drug-induced hepatotoxicity [12]. One of these patients was diagnosed with acute
cholangitis but a definitive diagnosis was not made in the other patient
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